Gyre Therapeutics (GYRE) Free Cash Flow (2010 - 2026)
Gyre Therapeutics (GYRE) reported Free Cash Flow of $3.0 million for Q1 2026, up 1303.98% year-over-year from $215244.6 in Q1 2025, and up 152.61% quarter-over-quarter from -$5.7 million in Q4 2025.
Gyre Therapeutics (GYRE) Free Cash Flow (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has 17 years of Free Cash Flow data on file, last reported at $3.0 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at $3.0 million, up 1303.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.1 million (up 134.8% YoY), and the FY2025 annual result was -$190000.0, up 96.81% from the prior year.
- Free Cash Flow grew to $3.0 million in Q1 2026 per GYRE's latest filing, from -$5.7 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $42.3 million in Q4 2022 and troughed at -$12.3 million in Q2 2022.
- A 5-year average of $1.5 million and a median of $1.0 million in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2024 and 2026: Free Cash Flow plunged 437.99% in 2024, then jumped 1303.98% in 2026.
- A 5-year view of Free Cash Flow shows it stood at $42.3 million in 2022, then tumbled by 97.55% to $1.0 million in 2023, then plunged by 359.94% to -$2.7 million in 2024, then sank by 113.29% to -$5.7 million in 2025, then surged by 152.61% to $3.0 million in 2026.
- Business Quant data shows GYRE's Free Cash Flow at $3.0 million in Q1 2026, -$5.7 million in Q4 2025, and $3.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Gyre Therapeutics | 554.75 Mn | 540.62 Mn | 8.38 Mn | 3.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.02 Mn |
| Mar 31, 2026 | 3.02 Mn |
| Dec 31, 2025 | -5.74 Mn |
| Dec 31, 2025 | -5.74 Mn |
| Sep 30, 2025 | 3.93 Mn |
| Sep 30, 2025 | 3.93 Mn |
| Jun 30, 2025 | 1.87 Mn |
| Jun 30, 2025 | 1.87 Mn |
| Mar 31, 2025 | -251,000.00 |
| Mar 31, 2025 | -251,000.00 |
| Dec 31, 2024 | -2.69 Mn |
| Dec 31, 2024 | -2.69 Mn |
| Sep 30, 2024 | 1.03 Mn |
| Sep 30, 2024 | 1.03 Mn |
| Jun 30, 2024 | -6.95 Mn |
| Jun 30, 2024 | -6.95 Mn |
| Mar 31, 2024 | 2.65 Mn |
| Mar 31, 2024 | 2.65 Mn |
| Dec 31, 2023 | 1.04 Mn |
| Dec 31, 2023 | 1.04 Mn |